Annual report
2112.TEDINET S100TUB8
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥31.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥27.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥25.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥23.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.5bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥622m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥731m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥906m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥731m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥498m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥609m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥775m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥776m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥498m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥27.5bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥25.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥26.1bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥27.2bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.5bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥13.8bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥14.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥13.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥9.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥8.9bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥447m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥792m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥227m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥374m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥711m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥481m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥602m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥456m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥53.95 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.28 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.43 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.58 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.65 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥500.79 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥403.93 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥381.21 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥365.4 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥328.42 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 49.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 11.9% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 76 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 77 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 82 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 80 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 87 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥21.2bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥19.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥18.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥17.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥18.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥258m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥315m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥595m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥850m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.7bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥315m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.2bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥205m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥395m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥585m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥657m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥24.8bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥23.7bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥24.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥25.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥12.7bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥13.8bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥12.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥9.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥9.5bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥9.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.4bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥753m | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥870m | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥45.17 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.52 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.55 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.59 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.27 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥9 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥444.67 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥361.28 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥348.28 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥339.76 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥310.17 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 49.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.6% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 35,000,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 43 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 44 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 45 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 51 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 50 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥14m |
| Otherother segments | employees | at 2024-03-31 | 1 pure |
| Otherother segments | revenue | 2023-04-01 → 2024-03-31 | ¥135m |
| Otherother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥118m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥16m |
| Otherother segments | segment assets | at 2024-03-31 | ¥1.1bn |
| Otherother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥65m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥13m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥33m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥82m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥82m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥10.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.3bn |
| Biotechnologyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥39m |
| Biotechnologyreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥59m |
| Biotechnologyreportable segment | employees | at 2024-03-31 | 6 pure |
| Biotechnologyreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Biotechnologyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Biotechnologyreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥38m |
| Biotechnologyreportable segment | segment assets | at 2024-03-31 | ¥1.6bn |
| Biotechnologyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥412m |
| Sugarreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥326m |
| Sugarreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥470m |
| Sugarreportable segment | employees | at 2024-03-31 | 41 pure |
| Sugarreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥29.7bn |
| Sugarreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥29.6bn |
| Sugarreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥27m |
| Sugarreportable segment | segment assets | at 2024-03-31 | ¥14.1bn |
| Sugarreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥366m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥544m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥82m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Otherother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥21m |
| Otherother segments | revenue | 2022-04-01 → 2023-03-31 | ¥134m |
| Otherother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥118m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥16m |
| Otherother segments | segment assets | at 2023-03-31 | ¥1.1bn |
| Otherother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥61m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥52m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥80m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥80m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥9.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Biotechnologyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥38m |
| Biotechnologyreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥64m |
| Biotechnologyreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.8bn |
| Biotechnologyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.8bn |
| Biotechnologyreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥36m |
| Biotechnologyreportable segment | segment assets | at 2023-03-31 | ¥1.7bn |
| Biotechnologyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥424m |
| Sugarreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥269m |
| Sugarreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥492m |
| Sugarreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥26.1bn |
| Sugarreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥26.1bn |
| Sugarreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥28m |
| Sugarreportable segment | segment assets | at 2023-03-31 | ¥13.7bn |
| Sugarreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥578m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥28.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥27.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥80m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥16.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Otherother segments | employees | at 2024-03-31 | 1 pure |
| Biotechnologyreportable segment | employees | at 2024-03-31 | 6 pure |
| Sugarreportable segment | employees | at 2024-03-31 | 8 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,502
| Item | Context | Value | Unit |
|---|---|---|---|
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.866 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.169 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.978 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.948 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.442 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.905 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.286 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.312 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.388 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.962 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00361-000SugarReportableSegmentsMember | 41 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00361-000SugarReportableSegmentsMember | 55 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00361-000BiotechnologyReportableSegmentsMember | 6 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00361-000BiotechnologyReportableSegmentsMember | 13 | |
| Number of employees | CurrentYearInstant_OtherReportableSegmentsMember | 1 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 28 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 2 | |
| Number of employees | CurrentYearInstant | 76 | |
| Average number of temporary workers | CurrentYearInstant | 70 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 43 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 43.2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 17.3 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6498000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00361-000SugarReportableSegmentsMember | 8 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00361-000BiotechnologyReportableSegmentsMember | 6 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OtherReportableSegmentsMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 28 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 43 | |
| Research and development expenses research and development activities | CurrentYearDuration | 40000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00361-000SugarReportableSegmentsMember | 326000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00361-000BiotechnologyReportableSegmentsMember | 39000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 13000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 379000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 35000000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 35000000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 35000000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 35000000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 33 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 107 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 29 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 18 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 11857 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 12058 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 38183 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 5168 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 57423 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |